Dong-A ST concludes co-sale agreement of antihypertensive ‘Edarbi’ with Takeda

Published: 2017-09-01 16:26:00
Updated: 2017-09-01 15:01:40

Dong-A ST announced on the 30th that conclusion of a joint sale and marketing agreement of ‘Edarbi,’ an ARB(angiotensin II receptor blocker) antihypertensive, with Takeda Pharmaceuticals Korea.

Under the agreement, Dong-A ST and Takeda Pharmaceuticals Korea will jointly carry out a business for ...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.